22q11 Deletion Syndrome
7
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
7 treatments under study, led by Athome Tacs Using Starstimhome Tes
Research Leaders
20 sponsors active, led by Natera, Inc.
Related Conditions
Often studied with 20 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (7)
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome
Mindfulness Program for Adolescents With 22q11DS
NB-001 in Children and Adolescents With 22q11 Deletion Syndrome
GROWing Up With Rare GENEtic Syndromes
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.
Research Network
Common Treatments
- Athome Tacs Using Starstimhome Tes1
- Omega3 Pufas1
- Sertraline1
- Retrospective File Studies1
- Standard Care1
Active Sponsors
- Natera, Inc.1
- Azrieli Foundation (Funder)1
- Alberta Health services1
- McMaster University1
- Unity Health Toronto1
Top Investigators
Holland Bloorview Kids Rehab Hospital
Innovation Research & Training
University of California, San Francisco
Montefiore Medical Center
Bambino Gesù Hospital and Research Institute
Related Conditions
- Tuberous Sclerosis2
- Praderwilli Syndrome2
- Neurofibromatosis1
- Myrhe Syndrome1
- Turner Syndrome1